Johnson & Johnson (NYSE:JNJ) Issues FY 2025 Earnings Guidance

Johnson & Johnson (NYSE:JNJ) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 10.800-10.900 for the period, compared to the consensus EPS estimate of 10.860. The company issued revenue guidance of $93.5 billion-$93.9 billion, compared to the consensus revenue estimate of $93.4 billion.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on JNJ. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Morgan Stanley lifted their price target on Johnson & Johnson from $176.00 to $178.00 and gave the company an “equal weight” rating in a research note on Friday. HSBC lifted their price target on Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Finally, Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $192.94.

Johnson & Johnson Trading Up 0.1%

Shares of JNJ stock opened at $190.88 on Tuesday. The firm has a market capitalization of $459.71 billion, a P/E ratio of 20.42, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $192.10. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock’s fifty day simple moving average is $178.88 and its 200 day simple moving average is $163.97.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is presently 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of JNJ. Semmax Financial Advisors Inc. grew its stake in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares in the last quarter. WealthCollab LLC boosted its position in shares of Johnson & Johnson by 9.9% during the 2nd quarter. WealthCollab LLC now owns 924 shares of the company’s stock worth $141,000 after acquiring an additional 83 shares in the last quarter. Rakuten Securities Inc. boosted its position in shares of Johnson & Johnson by 8.0% during the 2nd quarter. Rakuten Securities Inc. now owns 1,140 shares of the company’s stock worth $174,000 after acquiring an additional 84 shares in the last quarter. Blue Chip Partners LLC boosted its position in shares of Johnson & Johnson by 0.7% during the 2nd quarter. Blue Chip Partners LLC now owns 12,230 shares of the company’s stock worth $1,868,000 after acquiring an additional 86 shares in the last quarter. Finally, Strategic Wealth Investment Group LLC boosted its position in shares of Johnson & Johnson by 2.2% during the 2nd quarter. Strategic Wealth Investment Group LLC now owns 5,921 shares of the company’s stock worth $904,000 after acquiring an additional 126 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.